as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,112.9
Change
+20.3 (1.86%)
Open
₹1,087.1
Prev. Close
₹1,092.6
Day High
₹1,125.3
Day Low
₹1,079.1
Volume Analysis
Traded
237,313
Delivered
124,503
Delivery %
52.46%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (29.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (114.7%)
- •Strong 3-year revenue growth (162.5%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,178.64 | ₹1,151.97 | ₹1,132.44 | ₹1,105.77 | ₹1,086.24 | ₹1,059.57 | ₹1,040.04 |
| Fibonacci | ₹1,151.97 | ₹1,134.32 | ₹1,123.42 | ₹1,105.77 | ₹1,088.12 | ₹1,077.22 | ₹1,059.57 |
| Camarilla | ₹1,125.61 | ₹1,121.37 | ₹1,117.14 | ₹1,105.77 | ₹1,108.67 | ₹1,104.43 | ₹1,100.2 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+34.66%
1 Week
-8.55%
1 Month
-9.08%
3 Months
-26.46%
6 Months
+0.18%
1 Year
+34.77%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹35.02
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
15.14%
Net margin 19.05% × asset turnover 0.53x × equity multiplier 1.5x
Company Overview
Sector
Healthcare
Market Cap
₹5,125 Cr
P/E (TTM)
38.4
ROE
13.4%
Book Value
₹218.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.
TopFund Analysis
Senores Pharmaceuticals L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Growth (100/100), while Valuation (26/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (29.0%). Strong 3-year EPS growth (114.7%).
TopFund Score — Fundamentals Quality
66/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- −Stock is trading at 5.11 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has a low return on equity of 13.8% over last 3 years.
- −Company has high debtors of 187 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Subsidiary’s Mehsana facility received PIC/S GMP certification from Ukraine’s SMDC on November 16, 2026.
Senores Pharmaceuticals Limited has informed regarding transcript of earnings conference call held on October 29, 2026
Senores Pharmaceuticals Limited has informed regarding Newspaper publication extracts of unaudited financial results for the quarter and half year ended September 30, 2026
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 79 | 102 | 80 | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 | 192 |
| Expenses + | 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 126 | 135 |
| Operating Profit | 15 | 22 | 21 | 23 | 26 | 19 | 34 | 50 | 50 | 47 | 54 | 58 |
| OPM % | 19.0% | 22.0% | 27.0% | 23.0% | 25.0% | 17.0% | 25.0% | 31.0% | 29.0% | 27.0% | 30.0% | 30.0% |
| Other Income + | 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 7 | 18 | 3 | 9 |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 | 9 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 | 10 |
| Profit before tax | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 | 48 |
| Tax % | 31.0% | 19.0% | 19.0% | 18.0% | 20.0% | 13.0% | 20.0% | 26.0% | 25.0% | 23.0% | 23.0% | 23.0% |
| Net Profit + | 7 | 14 | 11 | 13 | 16 | 18 | 21 | 30 | 34 | 37 | 30 | 37 |
| EPS in Rs | 2 | 5 | 3 | 4 | 4 | 4 | 4 | 7 | 7 | 7 | 7 | 9 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 31 | 11 | 72 | 61 | 66 | 53 | 31 | 19 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales + | 8 | 14 | 35 | 215 | 398 | 633 | 719 |
| Expenses + | 7 | 12 | 23 | 173 | 309 | 464 | 509 |
| Operating Profit | 1 | 2 | 13 | 42 | 90 | 168 | 209 |
| OPM % | 13.0% | 14.0% | 36.0% | 19.0% | 23.0% | 27.0% | 29.0% |
| Other Income + | 0 | 0 | 4 | 3 | 19 | 47 | 37 |
| Interest | 0 | 1 | 2 | 9 | 22 | 25 | 30 |
| Depreciation | 1 | 1 | 2 | 10 | 17 | 31 | 37 |
| Profit before tax | 0 | 1 | 12 | 25 | 71 | 159 | 179 |
| Tax % | -110.0% | 13.0% | 32.0% | -31.0% | 17.0% | 24.0% | — |
| Net Profit + | 1 | 1 | 8 | 33 | 58 | 122 | 137 |
| EPS in Rs | 0 | 0 | 3 | 9 | 13 | 25 | 29 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | — | 149 | 507 | 86 | 59 | 39 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Reserves | 6 | 28 | 36 | 174 | 740 | 888 | 957 |
| Borrowings + | 4 | 15 | 63 | 258 | 315 | 342 | 417 |
| Other Liabilities + | 2 | 8 | 23 | 160 | 126 | 328 | 261 |
| Total Liabilities | 15 | 59 | 131 | 622 | 1,227 | 1,604 | 1,681 |
| Fixed Assets + | 2 | 7 | 27 | 235 | 301 | 523 | 851 |
| CWIP | 3 | 8 | 34 | 97 | 172 | 249 | 31 |
| Investments | 1 | 15 | 16 | 0 | 0 | 4 | 6 |
| Other Assets + | 9 | 29 | 53 | 289 | 754 | 827 | 792 |
| Total Assets | 15 | 59 | 131 | 622 | 1,227 | 1,604 | 1,681 |
| Equity Capital | 4 | 9 | 10 | 31 | 46 | 46 | 46 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -3 | -10 | -1 | -26 | -46 | 62 |
| Cash from Investing Activity + | -4 | -24 | -48 | -54 | -429 | -121 |
| Cash from Financing Activity + | 8 | 36 | 46 | 87 | 573 | -1 |
| Net Cash Flow | 1 | 2 | -3 | 8 | 98 | -60 |
| Free Cash Flow | -6 | -21 | -48 | -78 | -203 | -202 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -280 | -526 | 3 | -56 | -41 | 45 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Public | 38.2% | 40.39% | 41.03% | 41.3% | 41.54% | 40.92% | 37.78% | 37.32% |
| Promoters | 45.77% | 45.78% | 45.78% | 45.8% | 45.81% | 45.82% | 45.82% | 45.81% |
| FII | 4.25% | 4.17% | 3.66% | 4.28% | 3.35% | 3.64% | 6.62% | 6.01% |
| DII | 11.77% | 9.66% | 9.51% | 8.62% | 9.32% | 9.62% | 9.77% | 10.85% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Senores Pharmaceuticals L (this stock) | 5,125 | 38.4 | 5.11 | 13.4% |
| Morepen Lab. Ltd | 5,061 | 26.8 | 3.67 | 5.33% |
| Orchid Pharma Limited | 5,296 | 293.0 | 2.95 | 1.49% |
| Artemis Med Service Ltd | 5,415 | 46.2 | 5.47 | 12.0% |
| Sahajanand Medical Tech L | 5,427 | 75.6 | — | 10.4% |
| Sms Pharmaceuticals Ltd. | 4,758 | 40.7 | 5.64 | 14.3% |
| Iol Chem And Pharma Ltd | 5,587 | 26.4 | 2.91 | 8.41% |
Which Mutual Funds Hold Senores Pharmaceuticals L?
Frequently Asked Questions about Senores Pharmaceuticals L
Senores Pharmaceuticals L (SENORES) closed at ₹1,112.9 on NSE on 19 November 2026, up 20.3 (1.86%) from the previous close.
Senores Pharmaceuticals L trades on the NSE (National Stock Exchange of India) under the symbol SENORES.
Senores Pharmaceuticals L has a trailing twelve-month P/E (price-to-earnings) ratio of 38.4.
Senores Pharmaceuticals L has a dividend yield of 0.0%.
Senores Pharmaceuticals L's 52-week high is ₹1,600.0 and its 52-week low is ₹706.0.
Senores Pharmaceuticals L has a market capitalisation of ₹5,125 crore.
Senores Pharmaceuticals L has a TopFund Quality Score of 66/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Senores Pharmaceuticals L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.